On September 30, 2024, Senate Finance Chair Ron Wyden (D-OR) asked the Federal Trade Commission to address a new co-manufacturing practice by pharmacy benefit managers which he believes deters generic drug competition.
In a letter co-signed by Sen. Sherrod Brown (D-OH), Senator Wyden applauds FTC for suing the top three PBMs two weeks ago for allegedly inflating insulin prices through multiple business tactics, but he says the commission must also turn its attention to the new co-manufacturing practice. That practice, the senators allege, allows PBMs to generate more profit while also deterring generic and biosimilar competition and keeping drug costs high for patients.